Ardelyx appoints Mark Kaufmann as chief business officer

Role includes business development, licensing and strategic planning

Ardelyx, a US developer of oral therapeutics to correct metabolic disorders, has appointed Mark Kaufmann to the newly created position of chief business officer. The role at the Fremont, CA company will include business and corporate development, licensing, and strategic planning.

Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.

‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.

Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.

Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.

Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.

You may also like

Ingredients

Therapeutic: tenapanor for hyperphosphataemia

Patients with chronic kidney disease being treated with dialysis are at risk of developing hyperphosphataemia. This elevation of phosphorus levels is associated with cardiovascular morbidity and mortality
Manufacturing

Bracco enters cell therapy manufacturing with microbubble-based cell selection technology

Bracco Imaging is expanding into cell therapy manufacturing with a bead-free cell selection and activation technology based on its clinically validated microbubble platform
Medical Devices

Biocomposites gains MDR certification for STIMULAN antibiotic carriers

Biocomposites has secured EU MDR certification for its STIMULAN Rapid Cure and STIMULAN Kit products, enabling them to be mixed with multiple Gram-positive and Gram-negative antibiotics for infection management in bone and soft tissue
Pharma 5.0

New computational approaches could pave the way for safer medicines with fewer side effects

Advances in computational modelling and artificial intelligence are offering new ways to understand why medicines cause side effects and how to avoid them in future drug development
Digital

Shimadzu introduces a new site for its portfolio of LIB solutions

The website especially targets battery cell manufacturers, e-vehicle OEMs, research institutions as well as recycling companies and start-ups. There they will find Shimadzu’s latest solutions in the LIB market, including in-depth background information such as brochures and FAQs as well as featured highlight products
Hi Tech Manufacturing

Sustainable temperature control solutions at Analytica 2026

The presentation will highlight innovative equipment for laboratory and analytical applications
Medical Devices

Abbott hit with multiple FDA complaints in warning letter

The FreeStyle Libre manufacturer has been in the agency's line of fire after it deemed the company's response to previous letters "inadequate"
Subscribe now